Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, De Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New England J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012;56(5):1080–1088.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Lamarca A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol. 2017;11(1):75–83.
   PubMed Web of Science ®Google Scholar
• Lee SH, Song IH, Noh R, et al. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. J Gastroenterol Hepatol. 2015;15(1):1463–1469.
   Google Scholar
• Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12(2):243–253.
   PubMed Web of Science ®Google Scholar
• Cho JY, Paik Y-H, Lim HY, et al. Clinical parameters predictive of outcomes in sorafenib‐treated patients with advanced hepatocellular carcinoma. Liver Int. 2013;33(6):950–957. .
   PubMed Web of Science ®Google Scholar
• Yada M, Masumoto A, Motomura K, et al. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol: WJG. 2014;20(35):12581.
   PubMed Web of Science ®Google Scholar
• Nault J, Pigneur F, Nelson AC, et al. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. Dig Liver Dis. 2015;47(10):869–876.
   PubMedGoogle Scholar
• Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61(2):318–324. .
   PubMed Web of Science ®Google Scholar
• Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42(9):879–886. .
   PubMed Web of Science ®Google Scholar
• Kanbayashi Y, Hosokawa T, Yasui K, et al. Predictive factors for sorafenib-induced hand-foot skin reaction using ordered logistic regression analysis. Am J Health Syst Pharm. 2016;73(1):e18–23.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Expert Rev Anticancer Ther. 2014;14(6):751–760.
   PubMed Web of Science ®Google Scholar
• Massey PR, Okman JS, Wilkerson J, et al. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Supportive Care in Cancer. 2015;23(6):1827–1835.
   PubMed Web of Science ®Google Scholar
• Fishman MN, Tomshine J, Fulp WJ, et al. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. PloS One. 2015;10(4):e0120877.
   PubMed Web of Science ®Google Scholar
• Degen A, Alter M, Schenck F, et al. The hand‐foot‐syndrome associated with medical tumor therapy–classification and management. Jddg. 2010;8(9):652–661.
   Google Scholar
• Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411–1416.
   PubMed Web of Science ®Google Scholar
• Pragasam V, Verma R, Vasudevan B. Sorafenib and sunitinib: A dermatologist’s perspective. Indian Dermatol Online J. 2014;5(1):1.
   PubMedGoogle Scholar
• Di Costanzo GG, De Stefano G, Tortora R, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology. 2015;11(6):943–951. .
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(9):603–605.
   Google Scholar
• Yao X, Yan D, Liu D, et al. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Mol Clin Oncol. 2015;3(4):929–935.
   PubMedGoogle Scholar
• Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15(1):85–92.
   PubMed Web of Science ®Google Scholar
• Shomura M, Kagawa T, Shiraishi K, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014;6(9):670–676.
   PubMedGoogle Scholar
• Ogasawara S, Chiba T, Ooka Y, et al. Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Investigational New Drugs. 2015;33(3):729–739. .
   PubMed Web of Science ®Google Scholar
• Koschny R, Gotthardt D, Koehler C, et al. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2012;84(1):6–13. .
   PubMed Web of Science ®Google Scholar
• Ang C, O’Reilly EM, Abou-Alfa GK. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:225–246.
   PubMedGoogle Scholar
• Cheng AL, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Zhai B, Hu F, Jiang X, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther. 2014;13(6):1589–1598.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zheng T, Song R, et al. Hypoxia‐mediated sorafenib resistance can be overcome by EF24 through Von Hippel–Lindau tumor suppressor‐dependent HIF‐1α inhibition in hepatocellular carcinoma. Hepatology. 2013;57(5):1847–1857.
   PubMed Web of Science ®Google Scholar
• Zhang P, Li K-S, Shen Y-H, et al. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death & Disease. 2016;7(4):e2201.
   PubMedGoogle Scholar
• Del Prete S, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So. LAR. study. Cancer Chemother Pharmacol. 2010;66(5):837–844.
   PubMed Web of Science ®Google Scholar
• Marra M, Sordelli IM, Lombardi A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9(1):171 (1-14).
   PubMedGoogle Scholar
• Stiuso P, Potenza N, Lombardi A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Molecular Therapy-Nucleic Acids. 2015;4:e233.
   Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol. 2014;10(12):1981–1992.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta-analysis. Expert Rev Anticancer Ther. 2014;14(9):1063–1073.
   PubMed Web of Science ®Google Scholar